MM120 (LSD D-tartrate)

MM120 (now also referred to as DT120 ODT post-rebrand) is lysergide D-tartrate, pharmaceutical-grade LSD formulated as an orally disintegrating tablet, in Phase 3 development by Definium Therapeutics (Nasdaq: DFTX, formerly MindMed Inc., MNMD, rebranded January 9, 2026) [1][2][11]. The lead indications are generalized anxiety disorder (GAD) and major depressive disorder (MDD), with four Phase 3 trials active across the two indications. The pivotal Phase 2b in GAD reported a 21-point HAM-A (Hamilton Anxiety Rating Scale, a 14-item clinician interview scored 0 to 56) reduction at Week 12 after a single 100 µg dose, published in JAMA in 2025 [1]. Voyage topline in GAD is expected in H1 2026 and Panorama in H2 2026, with MDD readouts following in 2027.

MM120 is not a new chemical entity. LSD has been studied in humans since the 1940s, but no regulator has ever approved it for a medical indication. Definium's version is a crystalline D-tartrate salt in a Zydis orally disintegrating tablet administered at 100 µg in a supervised clinical setting. The lead program is in GAD, where the FDA granted Breakthrough Therapy Designation in March 2024 on the strength of the Phase 2b MM120-100 trial [7]. Four Phase 3 trials are now registered: Panorama (NCT06809595, n~245) and Voyage (NCT06741228, n~214) in GAD, Emerge (NCT06941844, n~149) and Ascend (NCT07592689, n~165) in MDD [2][3][4][5]. Panorama, Voyage, and Emerge are listed as active and not recruiting, suggesting enrollment is complete or nearly so. Ascend is still recruiting. Definium's Q2 2026 disclosures outline a 2027 NDA (New Drug Application) target in GAD if both pivotal trials read out positively, with MDD following roughly a year later [12]. A separate Phase 2a repeat-low-dose study in ADHD (NCT05200936, n=53) was completed; the company has not publicly disclosed topline efficacy data and the ADHD program has not advanced into Phase 3, which the company has framed as strategic prioritization toward GAD and MDD rather than a reported efficacy or safety failure [6].

LSD binds the 5-HT2A receptor, a protein on the surface of brain cells that normally responds to serotonin, the same neurotransmitter targeted by SSRIs. The difference is directness: an SSRI nudges background serotonin levels up by blocking its reuptake, while LSD directly activates 5-HT2A as a potent agonist, producing an acute hallucinogenic experience lasting 8 to 12 hours. The therapeutic bet is that this intense neuroplastic event, delivered once in a therapist-supported clinical setting, resets patterns of thought that drive chronic anxiety and depression. Preclinical work shows 5-HT2A agonism increases dendritic spine growth in the prefrontal cortex within hours of a single dose, with changes persisting for weeks. Target-level validation is strong: Open Targets scores HTR2A at 0.70 for MDD evidence, among the highest of any serotonin receptor. Clinically, psilocybin (another 5-HT2A agonist) has produced durable depression reductions in multiple academic trials, and Compass Pathways' COMP360 is in Phase 3 for treatment-resistant depression. The open question is not whether 5-HT2A agonism does something to mood circuits. It is whether the effect is durable, generalizable, and distinguishable from placebo in a trial where functional unblinding is essentially unavoidable.

Panorama (NCT06809595) is the lead GAD Phase 3: n~245, randomized, placebo-controlled, single supervised dose, with primary endpoint of change from baseline in HAM-A (Hamilton Anxiety Rating Scale, a 14-item clinician interview scored 0 to 56) at Week 12 [2]. Voyage (NCT06741228, n~214) runs the same design as a confirmatory GAD trial [3]. Ascend (NCT07592689, n~165) and Emerge (NCT06941844, n~149) test MDD with Week 6 MADRS (Montgomery-Åsberg Depression Rating Scale, a 10-item clinician interview scored 0 to 60) change as the primary endpoint, again single dose, placebo-controlled [4][5]. A 12-week durability endpoint in GAD after a single dose is a sharp commercial differentiator against daily benzodiazepines and SSRIs. The main design concern is functional unblinding: because HAM-A and MADRS are clinician-rated interviews, not objective biomarkers, patients and raters will usually know who received active drug based on the acute hallucinogenic experience, and that expectancy effect can inflate both arms. Definium has not publicly specified an active placebo. Enrollment status as of October 2026: Panorama, Voyage, and Emerge are active and not recruiting; Ascend is still enrolling. Voyage topline is expected H1 2026 and Panorama H2 2026, with MDD readouts tracking into 2027.

Our model estimates a 15% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 51%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual; it is held back by the sponsor's thin or weak approval record, weak or limited earlier-phase results, and heavier-than-usual blinding. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the dominant one. Functional unblinding means the placebo arm will not be truly blind, and the resulting expectancy effect can collapse the measured drug-versus-placebo delta even when the pharmacology works. Lykos Therapeutics' MDMA-for-PTSD NDA was rejected in 2024 largely over this concern, setting a difficult precedent for psychedelic Phase 3 interpretability [9]. Safety: single-dose 100 µg LSD has an acceptable acute profile in trials to date, but rare psychiatric events (prolonged dissociation, hallucinogen persisting perception disorder) and cardiovascular events (acute hypertension, tachycardia) scale with Phase 3 n. Execution: GAD trials have historically high placebo response, and HAM-A has subjective rater components. Commercial: even if approved, delivery requires an 8-to-12-hour supervised dosing session in a certified clinic with pre- and post-dose therapist contact. By comparison, psilocybin's acute session is 4 to 6 hours, so LSD programs face materially worse clinic throughput and payer economics per treated patient. The closest commercial analog is Spravato (esketamine, Johnson & Johnson), which crossed $1 billion in 2024 revenue [10], but a Spravato session is 2 hours. Scheduling: LSD is DEA Schedule I; approval requires rescheduling, a process that for psilocybin has been slow. IP: LSD itself is off-patent, but Definium holds US Patent 12,036,220 covering the MM120 ODT formulation, manufacturing, and method of treatment, with protection running through 2041, plus exclusive rights to Catalent's Zydis fast-dissolve technology for lysergide in major markets [13]. Dilution: Definium raised approximately $805 million gross in a June 2026 offering and ended Q2 2026 with roughly $1.1 billion in cash against ~$59 million quarterly operating burn, with company-stated runway into 2030, comfortably covering both pivotal GAD readouts, MDD readouts, and an NDA submission window without a forced raise [12].

Worth watching, specifically the Voyage GAD readout in H1 2026 and Panorama in H2 2026. This is the single most important data point in the psychedelic therapeutics category and will either validate or kill the thesis that single-dose 5-HT2A agonism produces durable anxiety reductions at pivotal scale. The specific signal to look for: HAM-A delta versus placebo at Week 12 of 7 points or greater with p<0.001, matching or exceeding the Phase 2b effect. Anything meaningfully smaller and the regulatory path narrows sharply, especially with two confirmatory trials required. Three check-back triggers: (1) Voyage topline (H1 2026) and Panorama topline (H2 2026); (2) FDA AdCom (FDA Advisory Committee) scheduling if Breakthrough status is maintained through NDA submission; (3) Compass Pathways COMP360 psilocybin-in-TRD Phase 3 readout, which will tell you whether the broader psychedelic class is converting Phase 2 signals into Phase 3 wins. Definium's Q2 2026 10-Q confirms cash into 2030 and removes near-term dilution overhang [12]. As a single-asset story, DFTX is a binary bet on these readouts, and the share price will move more on them than on anything else the company does.

GAD affects an estimated 6.8 million US adults (roughly 3.1% of the adult population per NIMH prevalence estimates) and MDD affects approximately 21 million US adults, so the headline TAMs are large. The realistic addressable population for MM120 is much smaller because of the supervised-session delivery constraint: patients must spend 8 to 12 hours in a certified clinic for a single dose, limiting adoption to treatment-resistant or motivated patients, and clinic throughput is a hard ceiling on near-term revenue. The Spravato ramp (approved 2019, >$1 billion revenue 2024) is the most relevant commercial template, and MM120's longer session will throttle per-clinic patient volume relative to Spravato.